Anti-Sjögren's syndrome-related antigen A antibody (Anti-SSA)

Anti-SSA/Ro antibodies are autoantibodies directed against the Ro52 (TRIM21) and Ro60 (TROVE2) ribonucleoprotein complexes, which are involved in RNA processing and the regulation of inflammatory responses (StatPearls, NBK537114; PubMed, 25635350). These antibodies serve as critical diagnostic biomarkers for systemic autoimmune rheumatic diseases, most notably Sjögren's syndrome and systemic lupus erythematosus (SLE) (NIH, Sjögren's Syndrome; StatPearls, NBK537114). While the antibodies themselves are not traditional therapeutic targets like receptors or enzymes, they are pathogenic drivers of disease, particularly in neonatal lupus where maternal IgG antibodies cross the placenta and cause inflammatory damage to the fetal heart, leading to permanent congenital heart block (PubMed, 25635350; UpToDate, Neonatal Lupus). Therapeutic interventions in patients positive for these antibodies typically focus on reducing their production through B-cell depletion therapies like Rituximab or modulating the immune response with agents such as Belimumab and Hydroxychloroquine (Rheumatology, 5892448; NIH, Sjögren's Syndrome). Monitoring the presence and levels of anti-SSA/Ro is essential for clinical management, risk stratification in pregnancy, and identifying patients at higher risk for extraglandular manifestations in Sjögren's syndrome (StatPearls, NBK537114).

Other names

Anti-Ro antibodyAnti-SSA antibodyAnti-Ro52Anti-Ro60Anti-SSA/Ro

B-cell depletion via CD20 targeting, inhibition of B-cell activating factor (BAFF), and immunomodulation to reduce autoantibody production and tissue damage.